Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.0000 (-4.91%) ($5.9800 - $6.5400) on Tue. Sep. 3, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.03% (three month average) | RSI | 45 | Latest Price | $6.0000(-4.91%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS declines -1.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(10%) LQD(6%) VCIT(6%) JETS(4%) SHY(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.515% in a week (0% probabilities). URA(-9%) INDA(-9%) XLE(-8%) USO(-7%) REMX(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.515% (StdDev 3.03%) | Hourly BBV | 0 () | Intraday Trend | -3.8% | | | |
|
Resistance Level | $6.14 | 5 Day Moving Average | $6.1(-1.64%) | 10 Day Moving Average | $6.1(-1.64%) | 20 Day Moving Average | $6.14(-2.28%) | To recent high | -6.5% | To recent low | 18.8% | Market Cap | $170m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |